A Phase 1, Open-label, Single-dose, Multi-center, Parallel Group Study to Evaluate the Pharmacokinetics of Tropifexor (LJN452) in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Control Subjects
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs Tropifexor (Primary)
- Indications Non-alcoholic steatohepatitis; Primary bile acid malabsorption; Primary biliary cirrhosis
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 28 Oct 2019 Status changed from recruiting to completed.
- 11 Jul 2019 Planned End Date changed from 25 Nov 2019 to 20 Nov 2019.
- 11 Jul 2019 Planned primary completion date changed from 25 Nov 2019 to 20 Nov 2019.